Company: ZVRA
Filing Date: 2025-04-10
Form Type: PREC14A
Source: 0000897069-25-000784
Chunk: 1

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-10
Form: PREC14A
Chunk 1
---
, Celebration, FL 34747, in connection with our solicitation of proxies for use at the 2025 Annual Meeting of Stockholders of the Company scheduled to be held on [●], 2025, at [●] Eastern Time, which will be held virtually on the internet at http://www.cesonlineservices.com/zvra25_vm and at any and all adjournments, continuations or postponements thereof (the “ Annual Meeting”). According to the Company’s proxy statement, the record date for the Annual Meeting is [●], 2025. Only stockholders of record at the close of business on that date may vote at the Annual Meeting or any continuation, adjournment or postponement thereof. This solicitation is being conducted by Mr. Daniel J. Mangless (the “ Proponent”), together with the other participants named herein (collectively, the “ Participants”). As of the date hereof, the Proponent beneficially owns an aggregate of 100 shares of Common Stock in record name and 1,521,095 shares of Common Stock in street name, representing approximately 2.8% of the shares of Common Stock, as reported to be outstanding by the Company as of March 7, 2025. As more fully discussed in this Proxy Statement, the proxies are being solicited to be used at the Annual Meeting for the following purpose: 1. To elect Mr. Travis C. Mickle, PhD and Mr. Arthur C. Regan (each of Messrs. Mickle and Regan, a “ Nominee”, and collectively, the “ Nominees”) as directors of Zevra (the “ Board of Directors” or the “ Board”). This Proxy Statement is first being sent or given to stockholders on or about [●], 2025. THIS SOLICITATION IS BEING MADE BY DANIEL J. MANGLESS, AND NOT ON
BEHALF OF THE BOARD OF DIRECTORS OF THE COMPANY. While the election at Zevra’s 2023 Annual Meeting of Stockholders brought about important change, including new leadership with extensive commercial experience, many other important issues remain unresolved to the detriment of all Zevra stockholders. This has resulted in the stock languishing despite the approval and successful initial launch of MIPLYFFA™ and subsequent sale of the PRV. My goal as a long-term stockholder of Zevra is for an independent Board to act in the best interests of all stockholders and follow best practices in corporate